|
Apr 7
|
Allogene Granted Three U.S. FDA Fast Track Designations (FTD) for ALLO-329, a Next-Generation Dual-Targeted CD19/CD70 Allogeneic CAR T, for the Treatment of Lupus, Myositis and Scleroderma
|
|
Mar 3
|
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update
|
|
Feb 26
|
Allogene Therapeutics Announces Participation in March Investor Conference
|
|
Feb 25
|
Allogene Therapeutics Expands Strategic Partnership with Foresight Diagnostics to Advance Joint Development Activities Outside the US Across Europe, UK, Canada, and Australia
|
|
Feb 13
|
Allogene Therapeutics Announces Publication of Durable Response Data from Phase 1 ALPHA/ALPHA2 Trials of the Allogeneic CAR T Cemacabtagene Ansegedleucel/ALLO-501 in Relapsed/Refractory Large B-Cell Lymphoma in the Journal of Clinical Oncology
|
|
Oct 3
|
Allogene Therapeutics, Inc. (ALLO): Among the Rising Penny Stocks to Invest In Now
|
|
Sep 30
|
Allogene Therapeutics Announces Participation in the Goldman Sachs Cell Therapy Day Conference
|
|
Sep 26
|
Allogene Therapeutics to Present Pre-Clinical Data Highlighting the Potential of ALLO-329, an Allogeneic CD19/CD70 Dual CAR T for the Treatment of Autoimmune Diseases, at the American College of Rheumatology (ACR) Convergence
|
|
Sep 18
|
IGM Biosciences (IGMS) Surges 11.6%: Is This an Indication of Further Gains?
|
|
Sep 14
|
Allogene Therapeutics, Inc. (ALLO): Short Seller Sentiment is Bearish on This Cancer Stock
|
|
Jun 20
|
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel), an Allogeneic CAR T Product, as Part of First Line Treatment for Patients with Large B-Cell Lymphoma (LBCL) Likely to Relapse
|
|
Jun 12
|
Allogene Therapeutics (ALLO) Down 13.9% Since Last Earnings Report: Can It Rebound?
|
|
May 23
|
Allogene Therapeutics Announces Participation in the TD Cowen 5th Annual Oncology Innovation Summit
|
|
May 14
|
Allogene (ALLO) Q1 Earnings in Line With Estimates, Sales Lag
|
|
May 14
|
Allogene Therapeutics Inc (ALLO) (Q1 2024) Earnings Call Transcript Highlights: Strategic ...
|
|
May 13
|
Allogene Therapeutics (ALLO) Reports Q1 Loss, Lags Revenue Estimates
|
|
May 13
|
Allogene Therapeutics Announces Pricing of $110 million Offering of Common Stock
|
|
May 13
|
Allogene Therapeutics Reports First Quarter 2024 Financial Results and Business Update
|
|
May 10
|
CollPlant Biotechnologies (CLGN) Soars 8.2%: Is Further Upside Left in the Stock?
|
|
May 6
|
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update
|